Mukolitics in the therapy of respiratory diseases in pediatric practice

• Published in: Medicinskij sovet no. 10; pp. 48 - 54
• Main Authors: Rashitova, E. L., Zakirova, A. M., Kadriev, A. G., Kadriev, A. A.
• Format: Journal Article
• Language: English
• Published: Remedium Group LLC 29-07-2020
• Subjects: bronchial obstructive syndrome; children; cough; mucolytic therapy; respiratory tract diseases
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2020-10-48-54

Introduction
. Mucolytic drugs are included in treatment standards and clinical guidelines for the management of children with respiratory diseases.
Target
. To study the effectiveness of mucoactive therapy through its comparative evaluation in pediatric practice with respiratory pathology.
Materials and methods
. A total of 48 patients (mean age 8.6 ± 4.1 years) with respiratory diseases were examined. They received conventional therapy and were divided into groups: the main one took Ambroxol (26) in syrup 15 mg/5 ml three times a day 4 days; comparison – a complex cough syrup with marshmallow (22) three times a day – 7 days. Dynamic control of clinical symptoms through statistical analysis and on special scales, accounting for clinical symptoms were evaluated out on the 1st, 3rd, 5th, 7th and 10th day from the start of mucoactive therapy.
Results and discussion
. The reception of ambroxol was accompanied by a pronounced muco-regulatory effect. On the 2nd day of treatment: significant relief of sputum discharge (p = 0.0002), dry cough stopped faster (p = 0.0007), wet cough remained in the recovery period for a short time (p = 0.003); by the 4th–6th day of treatment, a significant decrease in sputum volume and its production period (p = 0.017), shorter duration of dry (3.82 ± 0.84 and 1.79 ± 0.18 days; p = 0.022) and wet rales in the lungs (3.57 ± 0.78 and 1.61 ± 0.21 days; p = 0.024), the severity of dry cough in the main group by 5–7 days in children with allergopathology was less (p = 0.0001). On the 7th day, the severity of wet rales in patients of the main group was 0.08 ± 0.05 points, and in the comparison group 0.18 ± 0.07 points (p = 0.0003), the duration of wet cough (4.4 ± 0.23 against 5.71 ± 0.38 points), sputum discharge (4.63 ± 0.38 against 5.74 ± 0.35 points) and rhinorrhea (2.69 ± 0.57 against 4.42 ± 0.32 points) (p < 0.05).
Findings
. The clinical effectiveness of secretolitics is confirmed by reliably quick relief of dry and wet cough, sputum production intensity.